Research into XMRV and chronic fatigue syndrome (ME/CFS)
Posted by Cort Johnson The Singh Study was a big and important and its not surprising that, even prior to the WPI’s official response – everyone on both sides of the aisle is talking about it. Dr. Mikovits on the Singh Study – Science Mag reported that Dr. Mikovits was astounded that Dr. Singh was unable to find XMRV. Calling
ContinuePosted by Cort Johnson Dr. Singh’s study was one of the ‘biggies’ left. A murine retrovirologist at the University of Utah and the ARUP labs who had been studying (and finding) XMRV in prostate tissues, Dr. Singh started her CFS study about a year ago. Not only did it involve an expert in the field but Dr. Singh was working
ContinuePosted by Cort Johnson Dr. Deckoff Jones Opens Family Survey – Large scale surveys of illness in CFS families , for some reason, have not been done and yet they could open up a wealth of information about what ME/CFS is by showing what susceptibilities exist in the families. We did a poll on Phoenix Rising and was surprised by
ContinuePosted by Cort Johnson (There were some formatting and grammatical errors in the first post; this is a revised submission – my apologies) It wasn’t surprising at all to see things get heated with Dr. Coffin and Dr. Mikovits both up at bat at the State of Knowledge Workshop. The moderator, Dr. Alter, handled his job with humor and flair.
ContinuePosted by Cort Johnson Spinal Fluid Study Negative for XMRV and other Pathogens – A couple of weeks ago a Schutzer study found abnormal levels of proteins in the spinal fluid of people with ME/CFS but this NIH funded study found no evidence of either XMRV or common pathogens in the spinal fluid of people with ME/CFS. Dr. Schutzer stated
ContinuePosted by Cort Johnson I missed the meeting and the video is not up yet but got Dr. Mikovit’s slides and Alex provided a summary as well. (This is a little late but we’ve had trouble posting to the website lately). The high point of Dr. Mikovits talk was her report of finding an human signature of infection in her
ContinuePosted by Cort Johnson Big Changes at WPI – Dr. Lombard is taking over Dr. Mikovits position as Research Director and Dr. Mikovits is taking a new position as “Director of Translational Resources” Dr. Mikovits – The WPI’s brief announcement stated Dr Mikovits will now be focused on treatment rather than research; her new duties are to engage “in activities
ContinuePosted by Cort Johnson New Technology finds XMRV – Dr. Lapp sounds quite excited in his recent newsletter. Its not often you read Dr. Lapp reporting “that (the) information relayed this past week to us will change the field of medicine forever”..You don’t hear that very often! He reported that Dr. Urnovitz of Chronix Biomedical Labs. Chronix has developed an incredibly quick and inexpensive way of mapping
ContinuePosted by Cort Johnson This long interview may be difficult for some. In it Dr. Satterfield presents evidence which he believes suggests that XMRV will probably not work out. We’ve had this interview sitting in our laps for about 2 1/12 weeks during which we tried to get a response from the WPI . They, however, are too busy and
ContinuePosted by Cort Johnson MEDIA WEEK– this has been Media Week for XMRV as large stories have shown up in Nature Magazine, Wall Street Journal and Chicago Tribune or the past 10 days or so. Trine and the Trib on XMRV – Trine Tsouderous has carved out a place as a fierce skeptic of XMRV and the WPI over the
ContinuePosted by Cort Johnson Website Down (Again…sigh) – The website has been down for at least a week but hopefully we’re back up for good and in a new format. The website will changing quite a bit over time as we slowly create a new version of Phoenix Rising. Fighting for A Cause Dr. Mikovits and the search for XMRV was
ContinuePosted by Cort Johnson A New Center – Much research and discussion now is not centered around XMRV but around a prostate cancer cell line called 22RV1. More than anything else this cell line that is what is causing problems for XMRV. The 22RV1 cell line was created in 1999 in response to a need to study prostate cancer –
Continue